We use BPC-157 therapy as part of a holistic treatment plan, promoting faster recovery and overall improved well-being, allowing patients to regain an active lifestyle
Subchronic and chronic toxicity studies extending up to several months of continuous BPC-157 administration reveal no significant organ toxicity, hematological abnormalities, or pathological changes in treated animals compared to controls
Higher retatrutide doses (10-12 mg) produce more GI side effects and carry a higher risk of dysesthesia (tingling/numbness) without engaging the amylin pathway
Targeted at mature, post-menopausal, or estrogen-deficient skin
(PubMed) Lawson LD, Wang ZJ
Expect 30-40% reduction in severity, which often makes the difference between barely functional and tolerably uncomfortable